2006
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli E, Herbst RS. Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars In Oncology 2006, 33: 9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall response rateEpidermal growth factor receptorCell lung cancerLung cancerResponse rateSecond-line therapeutic approachStandard cytotoxic regimensFirst-line treatmentNew treatment optionsLung cancer casesQuality of lifeNew chemotherapeutic agentsCytotoxic regimensGrowth factor receptorRefractory settingMetastatic diseaseRefractory diseaseLocal therapyNSCLC treatmentTreatment optionsCancer deathTargeted therapyTreatment outcomesCancer cases
2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
Herbst R, Kim E, Harari P. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion On Biological Therapy 2001, 1: 719-732. PMID: 11727507, DOI: 10.1517/14712598.1.4.719.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Anti-epidermal growth factor receptor monoclonal antibodyAnti-EGFR monoclonal antibodiesMonoclonal antibodiesLocoregional disease recurrenceImportant adverse eventsPhase I studiesReceptor monoclonal antibodyExcellent response ratesTreatment of headHuman tumor xenograftsExtracellular receptor sitesInhibition of metastasisEnhanced tumor invasionPotent antitumour activityAnticancer treatment strategiesGrowth factor receptorCancer cell linesAdverse eventsRefractory diseaseSkin rashWeekly infusionsDisease recurrence